12:27 PM EDT, 06/20/2024 (MT Newswires) -- AbbVie ( ABBV ) said late Tuesday that Skyrizi has received approval from the US Food and Drug Administration for adults with moderately to severely active ulcerative colitis, expanding its portfolio across inflammatory bowel disease.

The company said data showed that the goals of clinical remission and endoscopic improvement were achieved with Skyrizi.

The approval brings the number of Skyrizi's indications to four, including as a treatment for adults with moderate to severe Crohn's disease, AbbVie ( ABBV ) said.

Price: 172.32, Change: +0.96, Percent Change: +0.56